In this prospective study, we aimed to compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.

Inclusion Criteria:

• the patients were the available data of clinical and laboratory diagnosis of sepsis and septic shock
• detection of gram-negative bacterial agent in blood or sputum culture.
• patients who had the shock symptoms such as hypotension, tachycardia or fever during the course of sepsis.

Exclusion Criteria:

• had uncontrolled hemorrhage,
• diagnosed with cardiac failure at stage 4 or renal failure at stage 4 or hepatic liver failure at stage 4
• cancer at the end stage or admitted with acute coronary syndrome.

In this one-centered study, we prospectively analyzed the outcomes and laboratory findings of 39 patients diagnosed with sepsis from 01 Jan 2020 to 30 December 2020 hospitalized in ICU.